Introduction
Type 1 diabetes (T1DM) 11 is an autoimmune disease resulting from specific T-lymphocyte-and reactive oxygen species (ROS)-mediated destruction of the insulin-producing b-cells of the islets of Langerhans in the pancreas (1) . It affects 1 in 300 people in the U.S. and is a major cause of mortality due to cardiovascular disease before 30 y of age (2) . As such, the mechanisms of b-cell death in T1DM need to be better understood. Previous studies have shown the involvement of zinc (Zn 2+ ) toxicity in streptozotocin models of T1DM in vitro or in vivo (3) (4) (5) . We have now examined more physiologic models of T1DM for the role of Zn 2+ toxicity. We have tested the hypothesis that Zn 2+ -and NAD + -mediated mechanisms are involved in b-cell toxicity in the mixed cytokine model of ongoing T1DM using mouse insulinoma cells and islets and in the nonobese diabetic (NOD) mouse.
NOD mouse model. The NOD mouse loses b-cells and glycemic control through autoimmune-mediated mechanisms accurately mimicking T1DM (1) . Immune-mediated ROS generation results in oxidative injury, depolarization, and degranulation of b-cells, causing secretory granular Zn 2+ release [reviewed in (6) ]. Inhibition of the metabolic enzymes GAPDH and pyruvate dehydrogenase causes an increase in triosephosphates as occurs in T1DM patients, perhaps mediated by a reduced NAD + :NADH ratio (7). Nicotinamide attenuates diabetes incidence in NOD mice, presumably by restoring this ratio (8) . These mechanisms are identical to those proposed for Zn 2+ neurotoxicity (9) (10) (11) , where pyruvate, nicotinamide, NAD + , and inhibition of Sir2 proteins attenuate neurotoxicity.
Streptozotocin. Streptozotocin is selectively toxic to pancreatic islets and a mouse b-cell insulinoma cell line (MIN6) causing reductions in NAD + :NADH, glucose oxidation, and glucose-induced insulin secretion (3, 12) . Streptozotocin induces Zn 2+ release, alkylates DNA-activating poly-ADP ribose polymerase and NF-kB, and depletes NAD + and ATP (3, 13, 14) . Oxygen radical scavengers, nicotinamide, Zn 2+ chelators, and pyruvate reduce streptozotocininduced diabetes incidence [this study and (3) (4) (5) 15) /insulin crystal formation (3) . Upon glucose induction and b-cell depolarization, insulin-bound and noninsulinbound Zn 2+ are released, both of which are cytotoxic to adjoining b-cells. This helps to explain the specificity of b-cell death (4, 16) . Because of this, dietary Zn 2+ supplementation has become controversial. The reasoning for supplementation is that type-2 diabetics (T2DM) and the elderly tend to be Zn 2+ deficient. Zn 2+ supplementation has been proposed to attenuate diabetes incidence (17) and T2DM but not T1DM animal models were reported to be Zn 2+ deficient [reviewed in (18) ]. This bimodality of Zn 2+ also occurs in neurons, where Zn 2+ is required for cell survival and supplementation is beneficial if concentrations are reduced but is toxic under pathologic conditions where labile Zn 2+ is in excess (19, 20) . Dietary Zn 2+ changes have been shown to induce changes in Zn 2+ transporters, depending on cell type, cellular localization, and the Zn 2+ transporter [reviewed in (21) ]. Intestinal expression of Zn 2+ importers, ZIP4 in particular, has been shown to be upregulated by dietary restriction. Pancreatic acinar cell expression of the Zn 2+ exporters ZnT1 and ZnT2 were shown to be reduced by dietary Zn 2+ restriction (22) . Under pathophysiologic, high-glucose, depolarizing conditions, the influx of Zn 2+ into islets and b-cells is predominantly mediated by voltage-gated calcium channels rather than by transporters (23) . Zn 2+ homeostasis in b-cells is genetically linked to T1DM and T2DM. Two slc30a family Zn 2+ transporters [Zinc transporter (ZNT) 5 and ZNT8] are preferentially or specifically expressed in b-cells and are involved in physiologic pancreatic Zn 2+ uptake into the Golgi and packaging into secretory granules (24, 25) . ZNT8 is a major epitope for autoantigen generation in T1DM, adversely affecting b-cell Zn 2+ transport and increasing pancreatic autoimmune attack (26) . A common single nucleotide polymorphism in ZNT8 is also linked to reduced susceptibility to T2DM (27) . However, global and/or b-cell knockout of ZnT5 or ZnT8 are not clinically diabetic. This suggests redundancy in b-cell Zn 2+ transport function (24, 28, 29) . In the studies described herein, we propose that diabetic immune-generated cytokines and ROS cause intracellular release of Zn 2+ or reuptake of noninsulin-bound Zn 2+ released exogenously by b-cell degranulation. This increased [Zn 2+ ] i potentiates loss of NAD + concentrations through Sir2 proteins, resulting in glycolytic inhibition, b-cell death, and diabetes incidence in ongoing T1DM (Supplemental Fig. 1 ).
Materials and Methods
Cell culture and toxicity studies. Cultures of the mouse insulinoma cell line MIN6 (from Dr. John Corbett, while at Washington University) were maintained as described (3) ; where indicated, cultures were preloaded with 10 mmol/L ZnCl 2 in the growth medium that did not affect cell number or viability. Then 35 mmol/L ZnCl 2 in serum-free minimal essential medium or 300 mmol/L ZnCl 2 in DMEM + 15% FBS was used for normal-density toxicities, and these conditions achieved similar levels of toxicity (Expt. 1). ZnCl 2 (400 mmol/L) in HEPES buffered salt solution with or without 60 mmol/L KCl replacing NaCl and Ca 2+ channel antagonists was present for 5 or 15 min in the [Zn 2+ ] i measurements as described (30) . For glucose deprivation (GD), normal-density cultures were washed 7 times in minimal essential medium lacking glucose and exposed in this medium plus normal growth additives with or without optimized concentrations of additional compounds for 24 h. The compounds used were: N,N,NÔN'-tetrakis(-)[2-pyridylmethyl]-ethylenediamine (TPEN), a Zn 2+ -specific chelator; sirtinol or 2-hydroxynaphthaldehyde (Naph), sirtuin (Sir2 protein) inhibitors; nimodipine and mibefradil, specific Land T-type calcium channel antagonists (10 mmol/L), respectively; and compounds that restored NAD + concentrations (pyruvate, nicotinamide, and NAD + ) at optimized concentrations (data not shown). High-density cultures (HDs) were used for streptozotocin and cytokine toxicities. MIN6 cells were collected, counted, resuspended in DMEM + 15% FBS, and plated at HD/low extracellular volume (;5-10 3 10 10 cells/L, in 0.04 mL) in V-shaped, 96-well plates (9) . These HDs were plated in 7.5 mmol/L streptozotocin or a mixture of cytokines (250 mg/L IL-1b, 8 mg/L, TNFa, and 200 mg/L IFNg) with coexposure to the compounds tested. High cytokine concentrations were required due to the HDs and short exposure (6 h, Expt. 2). Cell viability was assayed at varying times later by 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (MTT) staining (0.1% final) of individual wells of a tissue culture plate, the absorbance at 595 nm was then measured (n = 8-20 wells of cells from at least 3 independent experiments), and significance was tested using 1-way ANOVA (Expts. 1 and 2). Staining with propidium iodide (2.5 mg/L) for normal-density Zn 2+ and GD toxicity studies followed by measurement of fluorescence gave comparable results (data not shown). HDs were only assayed by MTT, because a monolayer culture is required for propidium iodide staining.
Isolated islet generation. Islets were generated from C57/Bl6/J mice (Jackson Labs) (31), recovered overnight, and handpicked into 24-well plates. Equivalent numbers of islets (;30) were put into each well in growth medium without phenol red. Alamar Blue (BioSource) was added (5%) to determine islet viability and basal fluorescence measured for islet content (excitation = 535 nm, emission = 595 nm). Islets were washed and exposed to 300 mmol/L Zn 2+ for 20 h or a mixture of IL-1b, TNFa, and IFNg (10, 4, 50 65 Zn 2+ and were used as the time points for the addition of antagonists. The stimulus solution was washed out 3 times with ice-cold quench buffer, cells lysed in SDS and counted (Supplemental Table 1 ), and significance was tested using 1-way ANOVA (Expt. 5).
[Zn 2+ ] i measurements. To monitor [Zn 2+ ] i , MIN6 cultures were washed and loaded with 5 mmol/L FluoZin-3-AM (excitation = 485 nm; emission = 530 nm) for 30 min. Cultures were then exposed as indicated and cellular fluorescence measured and compared with fluorescence in the presence of a Zn 2+ ionophore (delta max) compared with fluorescence in the presence of the Zn 2+ chelator TPEN (delta min). Calculations were performed exactly as described (30) and significance was tested using 1-way ANOVA (Expt. 6). FluoZin-3 is not influenced by the Ca 2+ or magnesium concentrations but weakly responds to other transition metals like lanthanum, mercury, or cadmium (33) .
Colony maintenance and trials. The NOD inbred mouse strain (Taconic) was maintained at Louisiana State University Health Sciences CenterÕs animal facility. Housing, killing, and anesthesia for all animals concurred with the institutional Animal Studies Committee guidelines and the Public Health Service Guide for the Care and Use of Laboratory Animals. Mice were killed by CO 2 asphyxiation followed by thoracotomy. The animal handler and tissue processor were unaware of the treatment conditions. Treatment began on 11 groups of age-matched, female, NOD mice (higher disease penetrance in females) at 6 wk of age. Plastic cages and water bottles with no metal were used for the duration to minimize Zn 2+ contamination. The treatment groups tested were nonpurified diet (Harlan diet no. 2019) + saline injection, + 200 mg Zn 2+ /L in the drinking water, + pyruvate (0.5 g/kg i.p. tri-weekly), and + Zn 2+ injections (100 mmol/kg/wk i.p. ZnSO 4 ). We also tested feeding a Zn (24) were backcrossed to NOD mice for 10 generations followed by interbreeding to obtain ZnT5
+/2 , and ZnT5 +/+ female mice in an NOD background, which were fed nonpurified diet (Expt. 8). Water and food ingestion and body weight were monitored weekly and did not significantly vary between groups (;5 mL of water and 5 g of food per mouse per day at 16 wk, decreasing to ;4 mL and 4 g at 32 wk). Blood glucose from fed mice was monitored every Monday afternoon starting at 10 wk; blood glucose from mice deprived of food for 6 h was determined periodically (glucose oxidase). These blood glucose samples gave qualitatively similar results. Mice akinetic with prodding or unable to eat and drink were killed and mortality was recorded; significance was tested using Kaplan-Meier estimates of the survival functions, with subsequent logrank tests and Sidak adjustment of P values. Multiple low-dose streptozotocin was performed (55 mg/kg i.p. injection each day for 5 d in C57/Bl6) and blood glucose was measured on d 0, 1, 4, 7, 14, and 21 (Supplemental Table 2 ) and significance was tested using a StudentÕs t test (Expt. 9).
Zn
2+ -restricted and nonpurified diets. The Zn
2+
-restricted diet and nonpurified diet were from Harlan Teklad, batch-labeled TD.85419 and no. 2019, respectively. The Zn 2+ -deficient diet was previously described (34) and the nonpurified diet is a proprietary standard diet (2019) made of corn and wheat with~19% protein, 14.7% total fiber, and 9% fat by weight, 0.060 g of Zn 2+ /kg diet, and 3.3 kcal/g of diet energy density. The datasheet for 2019 lists the ingredients and calculated nutrient value (Harlan Laboratories). The mineral and vitamin mixes used in 2019 are given in Supplemental Tables 3 and 4.
Zn
2+ staining. Ten-mm cryostat sections were dried and immersed in 5 mmol/L N-(6-methoxy-quinolyl)-para-toluenesulfonamide (TSQ) (Invitrogen/Life Technologies) for 2 min as described (3) (Expt. 10). Punctate Zn 2+ staining was determined using SISAnalysis counting software (Soft Imaging System) in 20 equivalently spaced sections (from 100) after TSQ staining (Expt. 11). ZinPyr-1 (ZP1; 5 mmol/L, TefLabs) staining was performed using dye in PBS for 2 min (11). Islet images were captured at identical exposures using a fluorescence microscope (Nikon TS-100) with a 10-203 air objective (Expt. 12). The intensity of insulin and ZP1 staining was measured by Image J software from NIH. Four to 8 images were measured per animal and 6 animals/group. The mean intensities were calculated and compared between the treated and untreated groups by a StudentÕs t test. Immunohistochemistry and hematoxylin/eosin staining were performed on adjacent postfixed sections.
Immunofluorescent technique. Sections were postfixed, permeabilized in 0.25% Triton X-100, labeled using anti-insulin (1:1000, Dako), developed, mounted with ProLong (Invitrogen/Life Technologies), and examined by epifluorescence microscopy (Nikon TS-100). The b-cell area was determined using SIS Analysis software in every tenth section (from 100) after insulin staining and significance was tested using 1-way ANOVA (Expt. 12).
Data analysis and statistics. All data are presented as mean 6 SEM. The n is given for each experiment in the legends. Each set of results was compared with the appropriate sham wash controls and toxin exposure alone by 1-way ANOVA using the DunnettÕs post hoc test and significance achieved by P < 0.05. The statistical analyses comparing the insulin or ZP1 staining intensities between 2 groups were compared by a StudentÕs t test. The statistical analyses for survival time or time until diabetes developed were performed where the curves for each genotype or treatment were compared with wild-type littermates or the normal Zn 2+ -containing diet. This was done using Kaplan-Meier estimates of the survival functions, with subsequent logrank tests and Sidak adjustment of P values from multiple comparisons among the genotype or treatment conditions (P < 0.05) (35) .
Reagents. Unless otherwise stated, all reagents were from Sigma Chemical. Table 1 ). These results agree with another report that studied [Zn 2+ ] i in islets, dispersed islet cells, and insulinoma cell lines (23) .
Results

MIN6 [
Pyruvate, nicotinamide, NAD + , and sirtuin inhibitors reduced Zn 2+ , streptozotocin, and cytokine toxicities. Compounds that attenuate Zn 2+ neurotoxicity were tested in b-cells. MIN6 cultures were exposed to Zn 2+ and GD under normal-density conditions or were exposed under high-density conditions to streptozotocin and cytokines as indicated; cell viability was determined by MTT staining (Fig. 2) . High-density insulinoma culture conditions mimic the islet structure, allowing release of endogenous Zn 2+ to attain toxic levels (3 . Control islets had 7 6 2% dissolution and b-cell release, whereas streptozotocin-exposed islets had 74 6 8% dissolution, which is significantly different (n = 10 wells). Islet Zn 2+ staining increased with age in NOD mice and was attenuated by reduced-zinc diet or knockout of ZnT5. Zn 2+ staining precedes death induced by Zn 2+ accumulation and was therefore tested in the islets of NOD mice. At 12, 15, 18, 21, and 24 wk, representative pancreatic sections were stained with hematoxylin/eosin, TSQ, ZP1, a-insulin, or anti-polyADP ribose ( Fig. 3; Table 3 ; Supplemental Fig. 2 ). Punctate Zn 2+ staining increased in islets in conjunction with lymphocyte infiltration in an age-dependent fashion starting at 15 wk. Some islets (especially minus pyruvate treatment) appeared to be degranulated, suggesting ongoing injury. Islets that were densely infiltrated with lymphocytes had punctate Zn 2+ staining and had lost insulin immunostaining (Supplemental Fig. 2 ). Anti-polyADP-ribose immunohistochemistry was not dramatically changed (data not shown). The reducedzinc diet (ZnR) (2 mg Zn 2+ /kg diet) or ZnT5 knockout (KO) in NOD decreased punctate and total pancreatic Zn 2+ staining and increased insulin staining ( Fig. 3; Table 3 ). Quantitation of the total Zn 2+ staining of all the conditions shown (Fig. 3) , whereas those from ZnT5 KO in NOD mice had 70.8 6 14 (n = 8-10), which differs (P < 0.05 by a StudentÕs t test).
In isolated islets and
Pyruvate or ZnR increased lifespan and b-cell mass and decreased diabetes incidence. Reducing Zn 2+ or pyruvate or nicotinamide exposure has been shown to attenuate Zn 2+ neurotoxicity in vivo (10,39) and so was tested in NOD mice. Female NOD mice were treated with 0.5 g/kg body weight (33/wk i.p.) of pyruvate, nicotinamide, or saline starting at 6 wk. An s.c. injection of pyruvate was also effective (data not shown). The b-cell mass in the pyruvate-treated or ZnR (2 mg Zn 2+ /kg diet) mice was greater than nonpurified diet or 60 mg Zn 2+ /kg purified diet controls, primarily because the islet number increased ( Fig. 3 ; Table 4 ; Supplemental Fig. 2 ). The insulin staining intensity also increased. Pyruvate treatment did not affect plasma cytokine concentrations, although a reduction was demonstrated for ZnR at 21 wk using a Bio-Rad multiplex. NOD mice without treatment and fed a normal Zn 2+ diet had 295 6 95 ng/L TNFa and 15,000 6 8000 U/L IL-1b. NOD + pyruvate-treated mice had 250 6 100 ng/L TNFa and 14,000 6 9000 U/L IL-1b, which is not different. NOD + ZnRtreated mice had 200 6 70 ng/L TNFa and 10,000 6 5000 U/L 
FIGURE 3 Pancreatic Zn
2+ and insulin staining in NOD mice exposed to ZnR and ZnT5 KO (Expt. 12). Fresh frozen and dried or fixed sections of pancreas from NOD mice at 21 wk of age that were fed the Zn 2+ diets indicated were stained with the Zn 2+ -specific fluorescent dye ZP1 or with anti-insulin. ZnT5 KO and WT littermates were fed a nonpurified diet. Representative epifluorescence photomicrographs of identical exposure were taken (n = 5-6). H & E, hematoxylin/eosin; NOD, nonobese diabetic; ZnR, reduced-zinc diet; ZnT, zinc transporter; ZP1, ZinPyr-1.
IL-1b, which is significantly different. Pyruvate did not affect lymphocyte infiltration or Zn 2+ staining, whereas ZnR significantly decreased Zn 2+ staining and reduced lymphocyte infiltration ( Fig. 3; Table 3 ; Supplemental Fig. 2 Fig. 4; Table 4 ). Furthermore, 260 mg Zn 2+ /kg diet potentiated diabetes incidence compared with a nonpurified diet that contained 60 mg Zn 2+ /kg (Fig. 4) . Quantitation of the total insulin staining of sections from conditions as in Figure 3 gave the following results. The insulin staining of pancreas from NOD mice fed a 60 mg Zn 2+ /kg diet had 13.3 6 3.8 RFU/mm 2 , whereas NOD mice fed 2 mg Zn 2+ /kg diet had 18.3 6 3.2, which is significantly different. The insulin staining of pancreas from ZnT5 WT/NOD mice had 25.7 6 11 RFU/mm 2 , whereas pancreas from ZnT5 KO/NOD mice had 40.3 6 19 (n = 8-10), which is different at P < 0.05 by a StudentÕs t test. Quantitation of the insulin or Zn 2+ staining for 1 or 260 mg Zn 2+ /kg diets and the ZnSO 4 injections was not possible, because very low numbers of islets remained. Pyruvate injection or 2 mg Zn 2 + /kg diet did not reduce blood glucose in C57/BL6 or young NOD mice and Zn 2+ injections had no effect on blood glucose or mortality in C57/BL6 mice. Pyruvate also attenuated diabetes incidence in the multiple low-dose streptozotocin model of diabetes (Supplemental Table 2 ).
ZnT5 KO mice in an NOD background had reduced diabetes incidence, mortality, and Zn 2+ staining. Knockout of the neuronal Zn 2+ transporter, ZnT3, has been shown to reduce Zn 2+ neurotoxicity, so knockout of a b-cell-enriched Zn 2+ transporter, ZnT5, was tested. Backcrossing of ZnT5 KO to NOD mice for 10 generations resulted in syngeneity such that or ROS exposure; global, focal, and retinal ischemias; hypoglycemia; head trauma; or target deprivation (9) (10) (11) 20, (39) (40) (41) .
Here, we demonstrated a similar mechanism in b-cells. Pyruvate and lactate, but not nicotinamide or NAD + , can be used as the sole energy source in MIN6 cells. Pyruvate regenerates NAD + in b-cells and is metabolized by their mitochondria (42) . The inability of lactate and the ability of pyruvate, nicotinamide, or NAD + to attenuate Zn 2+ , cytokine, and streptozotocin toxicities in insulinoma cultures, coupled with the potentiation of toxicities by the NAD + antagonist 3-acetylpyridine, showed that intracellular NAD + concentrations are involved in the mechanism. Loss of NAD + resulting in decreased glycolysis occurs in islets exposed to streptozotocin (12) . The changes in [NAD + ] i were not always proportional to the changes in cell survival with each therapeutic compound, indicating that additional pathways were important for the therapeutic effects of pyruvate and sirtinol ( Fig. 2A,C ] i . Pharmacologic, genetic, diabetic, or aging induced inhibition of the rate-limiting enzyme in NAD + synthesis, nicotinamide phosphoribosyl transferase, in islets or in vivo also causes reduced NAD + concentrations, reduced glucose tolerance, and reduced glucose-induced insulin secretion. These deficits could be restored by giving the product of the nicotinamide phosphoribosyl transferase enzyme (48, 49) . The protective effects of sirtinol and Naph and the antagonistic effects of resveratrol suggested that the NAD + -catabolic sirtuin pathway was involved.
Sirtuins are NAD + -dependent protein deacetylases that transfer modulatory acetyl groups from lysine residues of histones or transcription factors to NAD + , resulting in NAD + catabolism and transcriptional regulation [for review, see (44) ]. Overexpression of SIRT-1 in b-cells causes increased basal levels of glucoseinduced insulin secretion (50) . We showed that overexpression of SIRT-1 in b-cells in vitro made them more susceptible to Zn 2+ , streptozotocin, and cytokine toxicity (51) . We have implicated the sirtuin pathway in Zn 2+ and ROS-mediated neurotoxicity (10, 11 /kg diet = nonpurified diet). Blood glucose was monitored weekly and mice that demonstrated akinesia with continued prodding by an observer unaware of the treatment conditions were killed. (A) The number of mice whose blood glucose remained ,2.5 g/L for 2 consecutive weeks was plotted as a function of weeks of age. (B) The number of surviving mice was plotted as a function of weeks of age. *Different from sham injected mice, P , 0.05, n = 16. NOD, nonobese diabetic; P, pyruvate; ZnE, excess-zinc diet; ZnR, reduced-zinc diet. 
Zn
2+ deficiency can also attenuate the immune response, depending on cell type, concentration, and conditions [for review, see (54) ]. We observed a reduction in lymphocyte infiltration and serum cytokine concentrations, suggesting this mechanism is involved in the beneficial effects of ZnR on diabetes. concentration achieved in the susceptible tissues during pathological attack below that required for further toxicity (11, 53, 58) . Dietary Zn 2+ deficiency occurs in many elderly adults (59), but T1DM affects primarily adolescents and young adults. Therefore, we suggest that ZnR can attenuate T1DM by reducing both the immune attack and the noninsulin-bound labile Zn 2+ released from b-cells causing toxicity. ZnR may also be effective against other autoimmune diseases.
We wanted to genetically reduce pancreatic Zn 2+ concentrations. The effects of ZnT5 KO on NOD-induced diabetes were to reduce diabetes incidence, mortality, and pancreatic Zn 2+ staining. The effects of ZnT5 KO on the immune response are under study. ZNT5 is ubiquitously expressed in many cell types but is highly expressed in the pancreatic Golgi. Here, it is likely involved in maintaining Zn 2+ concentrations sufficient to allow loading into newly synthesized proteins and granular packaging. ZnT5 KO mice do not develop diabetes spontaneously, though a percentage of male mice have sudden cardiac arrest and mortality. ZNT5 expression is ubiquitous but highest in pancreas (24 (41, 60) . Oral pyruvate is used routinely in foods and as a body-building supplement without symptoms and i.p. pyruvate has been used in multiple animal models of injuries without off-target effects (11, 39, 41) . Pyruvate is not effective orally in attenuating injury; therefore, a pyruvate/insulin s.c. injection should be clinically tested.
